ArticleCureus2026
Maternal Bleeding Outcomes in Pregnant Women With Immune Thrombocytopenia (ITP): A National Database Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveImmune thrombocytopenic purpura (ITP) is a hematological disorder commonly affecting women of reproductive age, but limited studies explore the maternal morbidity in pregnant patients with ITP. This study aimed to investigate whether pregnant women with ITP are at higher risk of bleeding complications during and after delivery.
methodsWe analyzed the National Inpatient Sample (NIS) database for pregnant patients admitted for delivery from 2016 to 2018. Patients were stratified into two cohorts: those with ITP and those without. The two cohorts were matched in a 1:1 ratio based on multiple factors. Univariate and binary logistic regression analyses were used to evaluate outcomes, including intrapartum hemorrhage, postpartum hemorrhage, transfusion requirements, and mode of delivery. Results: Among 207,511 pregnant patients, 215 had ITP. Intrapartum hemorrhage was more frequent in the ITP cohort, though not statistically significant (0.9% vs. 0.3%; p=0.107). In contrast, postpartum hemorrhage was significantly higher in patients with ITP (10.2% vs. 4.4%; p<0.001). Transfusion requirements were similar between the two groups (2.3% vs. 1.4%; p=0.223). Mode of delivery did not differ significantly between cohorts (p=0.883), though patients with ITP requiring platelet transfusions were more likely to undergo C-section (83.3% vs. 51.5%; p=0.03). Intravenous immunoglobulin use did not significantly impact delivery mode (p=0.516). Conclusion: Pregnant patients with ITP have a significantly higher risk of postpartum hemorrhage, emphasizing the need for vigilant monitoring and proactive management. These findings highlight the importance of heightened peripartum surveillance and individualized management strategies to mitigate bleeding risk in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.